• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
  • GSK’s PD-1 inhibitor Jemperli approved in the UK pharmatimes
    June 08, 2021
    GlaxoSmithKline’s (GSK) PD-1 inhibitor Jemperli has been authorised by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of recurrent or advanced endometrial cancer.
  • FDA approves GSK’s Jemperli for endometrial cancer pharmaceutical-technology
    April 26, 2021
    The US Food and Drug Administration (FDA) has approved GlaxoSmithKline’s (GSK) programmed death receptor-1 (PD-1) blocking antibody Jemperli (dostarlimab-gxly) based on its Biologics License Application (BLA) for endometrial cancer.
  • Evrysdi leads latest CHMP recommendations pharmatimes
    March 02, 2021
    The European Medicines Agency’s (EMA) Committee for Medicines for Human Use (CHMP) has recommended six medicines for approval at its February meeting.

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Event Data Sharing Notice
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service